Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
4 July 2016 |
Main ID: |
EUCTR2013-001877-26-HU |
Date of registration:
|
06/09/2013 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
not applicable
|
Scientific title:
|
An open-label, multi-site trial to describe the safety and tolerability of oral cebranopadol administered for 26 weeks in subjects with cancer-related pain who have completed treatment in the KF6005/07 trial - CORAL XT – Open-label extension trial of the CORAL trial |
Date of first enrolment:
|
30/10/2013 |
Target sample size:
|
220 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-001877-26 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no
Randomised:
Open: yes
Single blind:
Double blind:
Parallel group:
Cross over:
Other:
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Austria
|
Belgium
|
Brazil
|
Bulgaria
|
Chile
|
Croatia
|
Denmark
|
France
|
Germany
|
Hungary
|
Mexico
|
Netherlands
|
Peru
|
Poland
|
Romania
|
Serbia
|
Slovakia
|
Spain
|
Sweden
|
United Kingdom
| | | |
Contacts
|
Name:
|
GRT Trial Information Desk
|
Address:
|
Zieglerstr. 6
52078
Aachen
Germany |
Telephone:
|
+492415693223 |
Email:
|
clinical-trials@grunenthal.com |
Affiliation:
|
Grünenthal GmbH |
|
Name:
|
GRT Trial Information Desk
|
Address:
|
Zieglerstr. 6
52078
Aachen
Germany |
Telephone:
|
+492415693223 |
Email:
|
clinical-trials@grunenthal.com |
Affiliation:
|
Grünenthal GmbH |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: Informed consent signed indicating that the subject understands the purpose of and procedures required for the trial and is willing to participate in the trial.
Subjects must be at least 18 years of age at the Enrollment Visit (Visit 1).
Women of childbearing potential must have a negative pregnancy test at Visit 1 and must not be lactating at Visit 1.
Subjects must be willing to use medically acceptable and highly effective methods of birth control.
Subjects who have completed treatment in KF6005/07 and are still in need of around-the-clock pain analgesia with strong opioids.
Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 128 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 92
Exclusion criteria: The subject has a clinically significant disease or condition other than cancer which in the investigator's opinion may affect efficacy or safety assessments.
Known to or suspected of not being able to comply with the protocol and the use of cebranopadol.
Subjects taking forbidden concomitant medications or not being able to follow the rules of use of concomitant treatment.
History of torsade de pointes and/or presence of risk factors for torsade de pointes (e.g., The subject has a clinically significant disease or condition other than cancer which in the investigator's opinion may affect efficacy or safety assessments.
Known to or suspected of not being able to comply with the protocol and the use of cebranopadol.
Subjects taking forbidden concomitant medications or not being able to follow the rules of use of concomitant treatment.
History of torsade de pointes and/or presence of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, bradycardia).
Concurrent participation in another trial (except participation in KF6005/07) or planning to be enrolled in another clinical trial (i.e., administration of experimental treatment in another clinical trial) during the course of this trial (this does not include observational studies), or previous participation in this trial. Employees of the sponsor, investigator, or trial site or family members of the employees, sponsor, or investigator.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
cancer-related pain MedDRA version: 18.0
Level: PT
Classification code 10058019
Term: Cancer pain
System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
|
Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]
|
Intervention(s)
|
Product Name: Cebranopadol 200 µg film-coated tablet Product Code: GRT6005 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Cebranopadol Current Sponsor code: GRT6005 Other descriptive name: CEBRANOPADOL Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200-
Product Name: Cebranopadol 400 µg film-coated tablet Product Code: GRT6005 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Cebranopadol Current Sponsor code: GRT6005 Other descriptive name: CEBRANOPADOL Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 400-
Product Name: Cebranopadol 600 µg film-coated tablet Product Code: GRT6005 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Cebranopadol Current Sponsor code: GRT6005 Other descriptive name: CEBRANOPADOL Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 600-
|
Primary Outcome(s)
|
Main Objective: The primary objective of this trial is to describe the safety and tolerability of prolonged exposure to cebranopadol in subjects suffering from cancer related pain
|
Primary end point(s): The primary endpoint for this trial is the incidence of treatment emergent adverse events (TEAEs).
|
Timepoint(s) of evaluation of this end point: First intake of IMP up to the time of the last protocol scheduled contact
|
Secondary Objective: Not applicable
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: Secondary safety endpoint: first intake of IMP up to the time of the last protocol scheduled contact. Secondary efficacy endpoint: last week during the Treatment Period and changes from baseline
|
Secondary end point(s): The secondary safety endpoint for this trial is the intensity of TEAEs. The secondary efficacy endpoint for this trial is the average pain intensity (11-point numerical rating scale [NRS]) in the last week during the Treatment Period and changes from baseline (Visit 1).
|
Secondary ID(s)
|
KF6005/09
|
2013-001877-26-SE
|
Source(s) of Monetary Support
|
Grünenthal GmbH
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|